{"id":21298,"date":"2023-05-25T08:07:29","date_gmt":"2023-05-25T12:07:29","guid":{"rendered":"https:\/\/medicarereport.org\/?p=21298"},"modified":"2023-05-25T08:07:31","modified_gmt":"2023-05-25T12:07:31","slug":"how-medicares-aduhelm-decision-revived-old-questions-about-new-drugs","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=21298","title":{"rendered":"How Medicare\u2019s Aduhelm decision revived old questions about new drugs"},"content":{"rendered":"\n<p>(By Kerry Dooley Young for ST<em>A<\/em>T)<\/p>\n\n\n\n<p>Medicare\u2019s decision to withhold coverage for Biogen\u2019s Aduhelm despite the Food and Drug Administration\u2019s approval of the Alzheimer\u2019s drug has revived longstanding questions about how the federal program determines whether it will pay for new drugs and devices.  Continue reading <a href=\"https:\/\/www.statnews.com\/2023\/05\/25\/medicare-aduhelm-cms-fda-pharmaceuticals\/\" data-type=\"URL\" data-id=\"https:\/\/www.statnews.com\/2023\/05\/25\/medicare-aduhelm-cms-fda-pharmaceuticals\/\">here&#8230;<\/a><\/p>\n\n\n\n<p><img loading=\"lazy\" decoding=\"async\" width=\"200\" height=\"21\" class=\"wp-image-4372\" style=\"width: 200px;\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\" alt=\"\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/p>\n\n\n\n<p class=\"has-small-font-size\"><strong>Notice:<\/strong>&nbsp;The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Kerry Dooley Young for STAT) Medicare\u2019s decision to withhold coverage for Biogen\u2019s Aduhelm despite the Food and Drug Administration\u2019s<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,32,31,6,15],"tags":[654,116,252,80,76,61],"class_list":["post-21298","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-cms","category-fda","category-medicare-general","category-part-dprescription-drugs","tag-aduhelm-drug","tag-alzheimers-disease","tag-alzheimers-treatment","tag-cms","tag-fda","tag-medicare"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21298"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21298\/revisions"}],"predecessor-version":[{"id":21299,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/21298\/revisions\/21299"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}